Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Lipodystrophy

• Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance
• Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Patients With PL
• A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)
• Changes in Weight, Body Composition and Cardiac Risk After Discontinuing Abacavir Treatment in HIV-infected Individuals
• Changes in Weight, Body Composition and Metabolic Parameters After Discontinuing Dolutegravir or Tenofovir Disproxil
• Effect of Berberine on Metabolic Syndrome, Efficacy and Safety in Combination With Antiretroviral Therapy in PLWH.
• A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS
• Contribution of Dolutegravir to Obesity and Cardiovascular Disease
• Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized Lipodystrophy
• Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy
• Cyclophosphamide in the Treatment of Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes
• Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL)
• Study of Gemcabene in Adults With FPLD
• Setmelanotide in a Single Patient With Partial Lipodystrophy
• Body Composition and Adipose Tissue in HIV
• Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)
• Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy
• CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy
• Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers
• Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension
• Energy Expenditure of People Living With HIV/AIDS
• The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy
• Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients
• Expanded Access Metreleptin Study
• Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
• Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
• Artefill for the Treatment of HIV-associated Facial Lipoatrophy
• An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects
• Egrifta Replacement and Sleep Disordered Breathing
• Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes
• Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
• Metabolic Abnormalities in HIV-infected Persons
• Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome
• Effects of IGF-I in HIV Metabolic Disease
• Effects of Growth Hormone Releasing Hormone in HIV
• HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)
• Clinical Trial to Assess the Effect of the Change of Efavirenz (EFV) for Lopinavir/Ritonavir (LPV/r) in Lipoatrophy in HIV-infected Patients
• Trial of Leptin Replacement Therapy in Patients With Lipodystrophy
• Prevention of Lipoatrophy in Patients Treated With Lopinavir/Ritonavir in Monotherapy Versus ZDV + 3TC + ABC
• Lopinavir/r Monotherapy Versus Abacavir/Lamivudine and Lopinavir/r for Limb Fat Recovery in Persons With Lipoatrophy
• Effects of Short-term Growth Hormone in HIV-infected Patients
• An Open-Label Treatment Protocol to Provide Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy
• Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome
• Raltegravir Therapy for Women With HIV and Fat Accumulation
• Study to Evaluate Changes in Limb Fat When Switching From a Thymidine Analogue
• Strategies of Interruption/Reinitiation of Antiretroviral Therapy in HIV-Infected Patients With Lipodystrophy
• Exercise and Pioglitazone for HIV-Metabolic Syndromes
• TH9507 Extension Study in Patients With HIV- Associated Lipodystrophy
• Therapeutic Approaches to HAART-Induced Lipodystrophy
• Mechanisms of Lipodystrophy in HIV-Infected Pateints
• Cholic Acid for Hepatic Steatosis in Lipodystrophy
• SHARE: Simple HAART With Abacavir, Reyataz, and Epivir
• Rosiglitazone Effect on Mitochondria and Lipoatrophy
• Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome
• Study Comparing Reducing the Dose of Stavudine Versus Switching to Tenofovir in HIV-Infected Patients Receiving Antiretroviral Therapy
• Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy
• Diet, Exercise, Niacin, and Fenofibrate to Reduce Heart Disease Risk Factors in Individuals With HIV Lipodystrophy or Dyslipidemia
• Pravastatin for Hyperlipidaemia in HIV.
• SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function
• Lactate Metabolism Study in HIV Infected Persons
• HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)
• Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects
• Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind, Placebo-Controlled Trial in 130 Patients
• Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome
• Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir.
• Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients
• Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome
• Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance
• TH9507 in Patients With HIV-Associated Lipodystrophy
• Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients
• Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy
• MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)
• The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients
• Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults
• Physiologic Growth Hormone Effects in HIV Lipodystrophy
• Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
• Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients
• Leptin to Treat Lipodystrophy
• Changing to Nonprotease Inhibitor Treatment to Improve Side Effects
• The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs
• Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities
• Safety and Effectiveness of Fenofibrate and Pravastatin in HIV-Positive Patients With Abnormal Blood Lipids
• A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy
• Underlying Abnormalities in Fat and Muscle Leading to Lipodystrophy Syndrome
• Leptin to Treat Lipodystrophy
• A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients
• A Study of Amprenavir in Patients With Protease Inhibitor-Related Complications